BIAS
RXRX icon

Beacon Investment Advisory Services’s Recursion Pharmaceuticals RXRX Stock Holding History

Beacon Investment Advisory Services’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$8.26K Hold
2,000
– – ﹤0.01% 645
2026
Q2 		$7.34K Hold
2,000
– – ﹤0.01% 650
2026
Q1 		$6.14K Buy
+2,000
New +$7.73K ﹤0.01% 679

Other funds holding RXRX

GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
CCIA
Cherry Creek Investment Advisors Englewood, Colorado $261M AUM 29.65% 1-Year Est. Return
WWM
Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return
KG
Kieckhefer Group Mequon, Wisconsin $252M AUM 40.97% 1-Year Est. Return
AWM
Accel Wealth Management Waverly, Iowa $464M AUM 21.88% 1-Year Est. Return
Wedmont Private Capital
Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
TWM
TriaGen Wealth Management Calabasas, California $413M AUM 35.91% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Beacon Investment Advisory Services's RXRX Position: Q3 2026 in Review

Beacon Investment Advisory Services held its Recursion Pharmaceuticals (RXRX) position steady in Q3 2026 at 2,000 shares worth $8.26K. The position accounts for ﹤0.01% of the portfolio, ranked #645.

Beacon Investment Advisory Services first reported a position in RXRX in Q1 2026 and has held it in 3 quarters since. 20 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • Beacon Investment Advisory Services held 2,000 shares of Recursion Pharmaceuticals worth $8.26K as of Q3 2026.
  • Beacon Investment Advisory Services left its Recursion Pharmaceuticals share count unchanged in Q3 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Beacon Investment Advisory Services's portfolio in Q3 2026, its #645 holding.
  • Beacon Investment Advisory Services first reported a position in Recursion Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • 20 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Beacon Investment Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.